Key facts
- OKYO - OKYO Pharma Ltd has 6 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 6 Insiders of OKYO Pharma Ltd
- Symbol
- OKYO on Nasdaq
- Location
- London, United Kingdom
Change
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 21 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
OKYO Pharma Ltd executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Gabriele M. Cerrone | Director, 10%+ Owner | $17,894,907 | Mixed | 18 Mar 2026 | ||
| Gary S. Jacob | Chief Development Officer, Director | $185,164 | Mixed | 18 Mar 2026 | ||
| John P. Brancaccio | Director | $25,005 | Mixed | 15 Sep 2023 | ||
| Bernard Denoyer | Director | Mixed | 16 May 2022 | |||
| Willy Jules Simon | Director | Mixed | 16 May 2022 | |||
| Keeren Shah | Chief Financial Officer | Mixed | 16 May 2022 |
Top shareholders of OKYO Pharma Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Jorey Chernett |
13D/G
|
Chernett Jorey |
9.5%
|
3,802,194
|
$11,824,823 | +$2,541,903 | 31 Dec 2025 | |
| Sirenia Capital Management LP |
13D/G
|
— |
7.7%
|
4,054,054
|
$6,202,703 | $0 | 31 Mar 2026 | |
| Woodline Partners LP |
13F
13D/G
|
Company |
7%
from 13D/G
|
3,652,190
|
$5,880,026 | — | 31 Mar 2026 | |
| Laura Natalia Monica Fonda |
13D/G
|
— |
5%
|
1,928,451
|
$3,856,902 | $0 | 22 Jul 2025 | |
| Dauntless Investment Group, LLC |
13D/G
13F
|
Company |
1.2%
|
471,523
|
$1,466,437 | -$6,066,133 | 31 Dec 2025 | |
| Gabriele M. Cerrone |
3/4/5
|
Director, 10%+ Owner |
20%
|
10,526,416
|
$17,894,907 | — | 18 Mar 2026 | |
| Gary S. Jacob |
3/4/5
|
Chief Development Officer, Director |
0.21%
|
108,920
|
$185,164 | — | 18 Mar 2026 | |
| Maven Securities LTD |
13F
|
Company |
2.3%
|
1,175,535
|
$1,892,611 | — | 31 Mar 2026 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
1.6%
|
850,000
|
$1,368,500 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.1%
|
584,796
|
$941,522 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.11%
|
59,760
|
$96,214 | — | 31 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0.07%
|
37,652
|
$60,620 | — | 31 Mar 2026 | |
| Cerity Partners LLC |
13F
|
Company |
0.02%
|
12,812
|
$20,627 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
12,090
|
$19,464 | — | 31 Mar 2026 | |
| EFG International AG |
13F
|
Company |
0%
|
923
|
$1,486 | — | 31 Mar 2026 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
152
|
$244 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
10
|
$16 | — | 31 Mar 2026 | |
| John P. Brancaccio |
3/4/5
|
Director |
—
class O/S missing
|
16,670
|
$25,005 | — | 15 Sep 2023 |
Recent Insider Transactions by Companies or Individuals for OKYO Pharma Ltd
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gary S. Jacob | OKYO | COMMON STOCK | 0 | 108,920 | 18 Mar 2026 | Direct | ||||
| Gabriele M. Cerrone | OKYO | COMMON STOCK | 0 | 10,526,416 | 18 Mar 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.